Technology Appraisal Virtual Committee Meeting

Committee A

Zoom

## Minutes: Confirmed

## Date and Time: Tuesday 14 July 2020, 9.30am - 2.30pm

### Present:

1. Dr Jane Adam (Chair) Present for all notes
2. Dr Brian Shine (Vice Chair) Present for all notes
3. Dr Peter Baker Present for all notes
4. Mr Richard Ballerand Present for all notes
5. Dr Andrew Champion Present for all notes
6. Dr Justin Daniels Present for all notes
7. Dr Steve Edwards Present for all notes
8. Dr Rita Faria Present for all notes
9. Dr Khalida Ismail Present for all notes
10. Ms Sumithra Maheswaran Present for all notes
11. Professor G.J. Melendez-Torres Present for all notes
12. Mrs Becky Pennington Present for all notes
13. Ms Pamela Rees Present for all notes
14. Dr Mohit Sharma Present for all notes
15. Dr Mark Upton Present for all notes
16. Dr Min Ven Teo Present for all notes
17. Dr Roger Whittaker Present for all notes

### In attendance:

* Janet Robertson, Associate Director, NICE, Present for all notes
* Thomas Feist, Project Manager, NICE, Present for all notes
* Marcia Miller, Administrator, NICE, Present for all notes
* Laura Marsden, Coordinator, NICE, Present for all notes
* Mandy Brereton, Assistant Project Manager, NICE, Present for all notes
* Faye Sheldon, Technical Analyst, NICE, Present for all notes
* Yelan Guo, Technical Adviser, NICE, Present for all notes
* Dwayne Boyers, Aberdeen HTA Group, Evidence Review Group, Present for notes 1 to 4
* Elisabet Jacobsen, Aberdeen HTA Group, Evidence Review Group, Present for notes 1 to 4
* Dolapo Ayansina, Aberdeen HTA Group, Evidence Review Group, Present for notes 1 to 4
* Professor Sean Whittaker, Clinical Expert, Professor of Skin Oncology, Present for notes 1 to 4
* Professor Julia Scarisbrick, Clinical Expert, Consultant Dermatologist, Present for notes 1 to 4
* Mr Stephen Scowcroft, Patient Expert, Director of Operations & External Affairs Lymphoma Action, Present for notes 1 to 4
* Professor Peter Clark, Cancer drugs Fund Clinical Lead, Present for all notes

### Non-public attendees:

* Emilene Coventry, Editor, NICE, Present for all notes
* Charlotte Fairclough, Technical Analyst, NICE, Present for notes 1 to 4
* Heidi Livingstone, Public Involvement adviser, NICE, Present for notes 1 to 4
* Rosalee Mason, Corporate Office Coordinator, NICE, Present for notes 1 to 4
* Sophie McHugh, Administrator, NICE, Present for all notes
* Sandra Robinson, Corporate Office Coordinator, NICE, Present for notes 1 to 4
* Adam Storrow, Business Analyst, NICE, Present for all notes
* Rebecca Thomas, Assistant Health Technology Assessment Analyst, NICE, Present for all notes

## Notes

### Any other Business

1. None

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Tuesday 9 June 2020.

## Appraisal of chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Recordati Rare Diseases/Helsinn Healthcare SA.
2. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests  
   1. Julia Scarisbrick declared a direct financial interest as she has previously worked in advisory roles for both Recordati Rare Diseases and Helsinn
      1. It was agreed that this declaration would not prevent Julie Scarisbrick from participating in this section of the meeting.
   2. Stephen Scowcroft declared an indirect interest as Lymphoma Action receive financial support to fund their work programme from pharmaceutical companies including Recordati Rare Diseases.
      1. It was agreed that this declaration would not prevent Stephen Scowcroft from participating in this section of the meeting.
   3. No further conflicts of interest were declared for this appraisal.
   4. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
   5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.
2. Agreement on the content of the Appraisal Consultation Document (ACD) was discussed by the committee.
3. The committee decision was based on consensus.

1. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.